MAZE
Maze Therapeutics Inc.

86
Mkt Cap
$2.47B
Volume
1.00
52W High
$53.65
52W Low
$6.71
PE Ratio
-22.74
MAZE Fundamentals
Price
$50.39
Prev Close
$51.26
Open
$51.02
50D MA
$44.90
Beta
1.02
Avg. Volume
500,688.63
EPS (Annual)
$0.0778
P/B
6.50
Rev/Employee
$1.34M
Loading...
Loading...
News
all
press releases
Maze Therapeutics (NASDAQ:MAZE) Stock Price Expected to Rise, Wedbush Analyst Says
Wedbush lifted their price target on shares of Maze Therapeutics from $43.00 to $58.00 and gave the company an "outperform" rating in a report on Monday...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Foresite Capital Management V LLC Sells 258,900 Shares of Maze Therapeutics, Inc. $MAZE
Foresite Capital Management V LLC lowered its position in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) by 75.0% in the third quarter, according to its most recent disclosure with the...
MarketBeat·2d ago
News Placeholder
Foresite Capital Management IV LLC Sells 1,589,262 Shares of Maze Therapeutics, Inc. $MAZE
Foresite Capital Management IV LLC lessened its holdings in Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) by 75.3% in the 3rd quarter, according to the company in its most recent disclosure...
MarketBeat·2d ago
News Placeholder
Boothbay Fund Management LLC Acquires 276,345 Shares of Maze Therapeutics, Inc. $MAZE
Boothbay Fund Management LLC grew its holdings in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) by 365.9% during the third quarter, according to the company in its most recent filing...
MarketBeat·3d ago
News Placeholder
545,132 Shares in Maze Therapeutics, Inc. $MAZE Acquired by ArrowMark Colorado Holdings LLC
ArrowMark Colorado Holdings LLC bought a new stake in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) in the third quarter, according to the company in its most recent Form 13F filing...
MarketBeat·3d ago
News Placeholder
Maze Therapeutics (NASDAQ:MAZE) CMO Sells $1,513,500.00 in Stock
Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) CMO Harold Bernstein sold 30,000 shares of the business's stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an...
MarketBeat·5d ago
News Placeholder
Maze Therapeutics (NASDAQ:MAZE) Rating Increased to Strong-Buy at Mizuho
Mizuho raised shares of Maze Therapeutics to a "strong-buy" rating in a research note on Wednesday...
MarketBeat·5d ago
News Placeholder
Maze Therapeutics (NASDAQ:MAZE) CMO Sells 30,000 Shares
Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) CMO Harold Bernstein sold 30,000 shares of the firm's stock in a transaction dated Tuesday, March 10th. The shares were sold at an average...
MarketBeat·5d ago
News Placeholder
Maze Therapeutics (NASDAQ:MAZE) Sets New 12-Month High - Should You Buy?
Maze Therapeutics (NASDAQ:MAZE) Sets New 1-Year High - Here's Why...
MarketBeat·7d ago
News Placeholder
Maze Therapeutics (NASDAQ:MAZE) Shares Up 8.5% - Here's Why
Maze Therapeutics (NASDAQ:MAZE) Trading Up 8.5% - Still a Buy...
MarketBeat·8d ago
<
1
2
...
>

Latest MAZE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.